Loren Data's SAM Daily™

FBO DAILY ISSUE OF APRIL 12, 2006 FBO #1598
SOLICITATION NOTICE

A -- 2006 MEDICAL SCIENCE AND TECHNOLOGY (S&T) CHEMICAL AND BIOLOGICAL DEFENSE TRANSFORMATIONAL MEDICAL TECHNOLOGIES INITIATIVE (TMTI)

Notice Date

10/31/2005
 

Notice Type

Solicitation Notice
 

NAICS

541710 — Research and Development in the Physical, Engineering, and Life Sciences
 

Contracting Office

Other Defense Agencies, Defense Threat Reduction Agency, Defense Threat Reduction Agency (Headquarters), DTRA Annex 8725 John J. Kingman Road, MSC 6201, Fort Belvoir, VA, 22060-6201
 

ZIP Code

22060-6201
 

Solicitation Number

DTRA01-06-BAA-01
 

Response Due

1/3/2006
 

Point of Contact

Katherine Luhmann, Supervisory Contract Specialist, Phone (703) 325-1197, Fax (703) 325-9295, - Janice Washington, Contract Specialist, Phone 703-325-9625, Fax 703-325-9295,
 

E-Mail Address

kathy.luhmann@dtra.mil, janice.washington@dtra.mil
 

Description

THIS IS A COMBINED SYNOPSIS/SOLICIATION. The purpose of this Broad Agency Announcement (BAA) is to solicit proposals for the Department of Defense (DoD) during Fiscal Year 2006 and possible future years Medical Science and Technology (S&T) Chemical and Biological Defense Transformational Medical Technologies Initiative (TMTI). The DoD conducts a vigorous medical research and development program in chemical and biological defense with the goal of protecting the warfighter from disease and biological and chemical warfare agents. The CBDP seeks to develop counter-measures that can be brought into acquisition and fielded worldwide. These products must be regulatory compliant, robust, and highly effective at a reasonable cost. Successful candidates must demonstrate a clear path to regulatory approval, production and end user utility. They must all be amenable to use in a military environment. This BAA is focused on developing medical counter-measures to ermerging threats, genetically engineered and nontraditional toxins, virulence factors and microorganisms as biological warfare (BW) threat agents. An important consideration is a more expedient approach and/or a shorter timeline to advanced development for a potential product. It is anticipated that these counter-measures would include pre-treatments (including vaccine enhancement technology), therapeutics and basic science to characterize the nature of the threat and identify key targets for intervention or disruption of these agents. The agent classes that are to be focused on are: intra-cellular bacterial pathogens, hemorrhagic fever viruses and bioregulators. Approaches to the objectives for this area include studying the genetic diversity and pathogenicity of natural isolates, identifying common structural elements of specific agents or classes of agents (preferred), elucidating common virulence mechanisms (such as type III secretory proteins), identifying functional domains in toxins and virulence factors, and using this information to develop rapid and effective medical countermeasures protecting against genetically engineered or emerging BW threats. NOTE: THIS NOTICE MAY HAVE POSTED ON FEDBIZOPPS ON THE DATE INDICATED IN THE NOTICE ITSELF (31-OCT-2005). IT ACTUALLY APPEARED OR REAPPEARED ON THE FEDBIZOPPS SYSTEM ON 10-APR-2006, BUT REAPPEARED IN THE FTP FEED FOR THIS POSTING DATE. PLEASE CONTACT fbo.support@gsa.gov REGARDING THIS ISSUE.
 

Web Link

Link to FedBizOpps document.
(http://www.fbo.gov/spg/ODA/DTRA/DTRA01/DTRA01-06-BAA-01/listing.html)
 

Place of Performance

Address: 8725 John J. Kingman Road, MS 6201, Fort Belvoir, VA

Zip Code: 22060

Country: USA
 

Record

SN01025234-F 20060412/060410221454 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |